Texas-based developer of advanced computer vision systems for breast cancer detection, VuCOMP, announced the formation of a new strategic medical advisory board composed of international breast imaging experts. The experts will support the company’s research work on product development strategies, as well the understanding of the clinical and business challenges facing their customers.
The new strategic advisory board, which includes not only the director of the Center for Breast Care and the George and Carol Poston Professorship in Breast Cancer Research and three other American scientists, but also experts from Austria and Germany, will guide the continuous development of computer-aided detection (CAD) solutions using tomosynthesis, a method for performing high-resolution, limited-angle tomography at mammographic dose levels.
“We are pleased to have such an experienced and knowledgeable medical advisory board to help guide VuCOMP in the development of the most effective and clinically relevant products possible,” said VuCOMP President James Pike. “Vital to our success is truly understanding, in great depth, both the clinical needs of our customers, as well as how our products enhance their workflow. Their insights will help us to achieve these objectives.”
The director of the Center for Breast Care and the George and Carol Poston Professorship in Breast Cancer Research in Dallas, W. Phil Evans, MD, FACR, was one of those chosen to integrate the board, along with Debra Copit, MD, FACR, clinical associate professor of radiology at Jefferson Medical College and director of Breast Imaging at the Albert Einstein Medical Center in Philadelphia, Pennsylvania, as well as Elizabeth Morris, MD, Chief of Breast Imaging Services of the Memorial Sloan-Kettering Cancer Center in New York.
Michael Linver, MD, the director of Mammography, X-Ray Associates of New Mexico, P.C. and Clinical Professor of Radiology at the University of New Mexico School of Medicine, New Mexico, is one of the other members. International experts include the Chief of the Breast Imaging Section of the University of Vienna, Austria, Katja Pinker-Domenig, MD, and the Head of Clinic Gyn. Radiology, Kliniken-Essen Mitte, in Germany, Frank Stöblen, MD. VuCOMP plans to expand the board in the coming months and include more members with similar profiles.
VuCOMP currently has two breast imaging products. Last April, its system M-Vu Breast Density 2.0 became the first and only commercially available, FDA cleared product to target breast cancer detecting fibroglandular volume, density and dispersion of breast tissues. After the examination, the data is compared to the standard set of the American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS), which provides highly accurate imaging and data using algorithms formulated by 13 of the company’s radiologists.
The 3.1 version of the M-Vu Computer-Aided Detection (CAD) for mammography was also approved in June by the FDA and it is capable of identifying the areas in a mammogram that may indicate breast cancer, also using advanced computer vision algorithms. The approval followed a series of effectiveness trials, as the first versions of the system was already being use by physicians.
Both products are being used in the market, as the company continues to set new standards for CAD and automated breast density measurement. Mammography CAD systems have been approved by the FDA since 1998.